NFL Biosciences SA, a biopharmaceutical ncompany that is developing botanical drugs for the treatment of naddictions, and Diverchim, a French market leader for the GMP ndevelopment and production of novel molecules, are announcing that they have set up a partnership. Diverchim will manage the production of liquid protein extracts from tobacco and cannabis leaves, which are the core componentsnof NFL-101, NFL Biosciences’ botanical drug candidate for the treatmentnof tobacco addiction, and NFL-201, for treating cannabis dependence.
Diverchim Activities Are Takeover By Group of Investors